Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4770404 | 0.91 | HDAC1 (0.53) | HDAC1ALDH1A1HDAC3HDAC7HDAC2 | |
| SCHEMBL28173281 | 0.86 | AKT1 (0.44) | HDAC1ALDH1A1HDAC3HDAC7HDAC2 | |
| Hydrochloric Acid SCHEMBL28173275 | 0.85 | AKT1 (0.43) | HDAC1ALDH1A1HDAC3HDAC7HDAC2 | |
| SCHEMBL2221 | 0.84 | AKR1C1 (0.55) | HDAC1ALDH1A1AKR1C1 | |
| SCHEMBL3910628 | 0.83 | AKR1C1 (0.53) | HDAC1ALDH1A1AKR1C1 | |
| SCHEMBL29473164 | 0.83 | HDAC1 (0.42) | HDAC1ALDH1A1HDAC3HDAC7HDAC2 | |
| SCHEMBL2130769 | 0.83 | OPRL1 (0.44) | HDAC1ALDH1A1HDAC3HDAC7HDAC2 | |
| Water SCHEMBL3910626 | 0.81 | AKR1C1 (0.52) | HDAC1ALDH1A1AKR1C1 | |
| SCHEMBL1335906 | 0.79 | ESR2 (0.48) | ALDH1A1HDAC4CA1CA2HSD11B1 | |
| SCHEMBL23588019 | 0.78 | SLC18A3 (0.43) | HDAC1ALDH1A1HDAC3HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1625554-A | Amides of aminoalkyl substituted azetidines, pyrrolidines, piperidines and azepanes | NOVO NORDISK AS (DK) | 2005-06-08 | — | — | CN | disclosed |
| EP-1472244-A1 | AROMATIC SULFONE HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS | Pharmacia Corporation (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040209914-A1 | Aromatic sulfone hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION | 2004-10-21 | — | — | US | disclosed |
| US-6683093-B2 | ENZYME INHIBITORS; CARDIOVASCULAR DISORDERS; ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE | PHARMACIA CORPORATION | 2004-01-27 | — | — | US | disclosed |
| WO-2003045944-A1 | AROMATIC SULFONE HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-06-05 | — | — | WO | disclosed |
| US-20030073718-A1 | Aromatic sulfone hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073718-A1 | Aromatic sulfone hydroxamic acids and their use as protease inhibitors | MMP1, MMP7, MMP3 | HDAC1 95/4885ALDH1A1 564/4885HDAC3 116/4885 |
| US-20040209914-A1 | Aromatic sulfone hydroxamic acids and their use as protease inhibitors | MMP1, MMP7, MMP3 | HDAC1 95/4885ALDH1A1 564/4885HDAC3 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.